𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial

✍ Scribed by Bao, C.; Huang, F.; Khan, M. A.; Fei, K.; Wu, Z.; Han, C.; Hsia, E. C.

Book ID
126925422
Publisher
Oxford University Press
Year
2014
Tongue
English
Weight
463 KB
Volume
53
Category
Article
ISSN
1462-0324

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Efficacy and safety of golimumab in pati
Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial
✍ Robert D. Inman; John C. Davis Jr.; DΓ©sirΓ©e Van Der Heijde; Laura Diekman; Joach πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 168 KB πŸ‘ 2 views

## Abstract ## Objective To evaluate the efficacy and safety of golimumab in patients with ankylosing spondylitis (AS) in the GO‐RAISE study. ## Methods Patients with active AS, a Bath AS Disease Activity Index (BASDAI) score β‰₯4, and a back pain score of β‰₯4 were randomly assigned in a 1.8:1.8:1

Six-month results of a double-blind, pla
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis
✍ J. Brandt; A. Khariouzov; J. Listing; H. Haibel; H. SΓΆrensen; L. Grassnickel; M. πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 118 KB πŸ‘ 2 views

## Abstract ## Objective There is increasing evidence that tumor necrosis factor Ξ± (TNFΞ±) is centrally involved in the pathogenesis of ankylosing spondylitis (AS) and other spondylarthritides. This study was designed to investigate the efficacy of anti‐TNFΞ± therapy with etanercept, a 75‐kd recepto